Retatrutide is an investigational compound not approved by the FDA for any indication
10.1177/07334648211073129 J
Tosto R, Vecchio G, Bellia F
Low levels of albumin may indicate poor liver function, low glutathione levels, low levels of antioxidants, oxidative stress, or protein deficiency
Clinicians managing patients on testosterone who wish to explore retatrutide should: Consult the relevant clinical trial protocols if the patient is enrolled in a study Seek specialist endocrinology input before initiating any off-label or investigational combination Document clinical rationale clearly , obtain informed consent, and follow GMC Good Practice in Prescribing and Managing Medicines and Devices guidance when considering unlicensed or investigational treatments Until formal guidance is available, clinical decision-making should be guided by individual patient riskbenefit assessment, informed consent, and regular monitoring
PMID 28843240
